Article
Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jan 2013
Wheeler Heather E, Gamazon Eric R, Wing Claudia, Njiaju Uchenna O, Njoku Chidiamara, Baldwin Robert Michael, Owzar Kouros, Jiang Chen, Watson Dorothy, Shterev Ivo, Kubo Michiaki, Zembutsu Hitoshi, Winer Eric P, Hudis Clifford A, Shulman Lawrence N, Nakamura Yusuke, Ratain Mark J, Kroetz Deanna L, Cox Nancy J, Dolan Mary Eileen
Abstract excerpt
PURPOSE: We sought to show the relevance of a lymphoblastoid cell line (LCL) model in the discovery of clinically relevant genetic variants affecting chemotherapeutic response by comparing LCL genome-wide association study (GWAS) results to clinical GWAS results. EXPERIMENTAL DESIGN: A GWAS of paclitaxel-induced cytotoxicity was conducted in 247 LCLs from the HapMap Project and compared with a GWAS of sensory...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
